Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma

Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome

Susan D. Demo, Christopher J. Kirk, Monette Aujay et al. · Cancer Research · 2007 · 668 citations · Full text

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

David S. Siegel, Thomas G. Martin, Michael Wang et al. · Blood · 2012 · 654 citations · Full text

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib

Paul G. Richardson, Hannah Briemberg, Sundar Jagannath et al. · Journal of Clinical Oncology · 2006 · 644 citations · Full text

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

Owen A. O’Connor, A. Keith Stewart, Marcy K. Vallone et al. · Clinical Cancer Research · 2009 · 298 citations · Full text

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

Melissa Alsina, Suzanne Trudel, Richard R. Furman et al. · Clinical Cancer Research · 2012 · 143 citations